Form 8-K - Current report:
SEC Accession No. 0001193125-25-151393
Filing Date
2025-06-27
Accepted
2025-06-27 16:55:46
Documents
19
Period of Report
2025-06-25
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d85382d8k.htm   iXBRL 8-K 40914
2 EX-1.1 d85382dex11.htm EX-1.1 214820
3 EX-4.1 d85382dex41.htm EX-4.1 76120
4 EX-5.1 d85382dex51.htm EX-5.1 9820
5 EX-10.1 d85382dex101.htm EX-10.1 90370
6 EX-99.1 d85382dex991.htm EX-99.1 10057
7 EX-99.2 d85382dex992.htm EX-99.2 10974
11 GRAPHIC g85382dsp88.jpg GRAPHIC 5765
  Complete submission text file 0001193125-25-151393.txt   690933

Data Files

Seq Description Document Type Size
8 XBRL TAXONOMY EXTENSION SCHEMA kymr-20250625.xsd EX-101.SCH 2854
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE kymr-20250625_lab.xml EX-101.LAB 17995
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE kymr-20250625_pre.xml EX-101.PRE 11264
21 EXTRACTED XBRL INSTANCE DOCUMENT d85382d8k_htm.xml XML 3646
Mailing Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472
Business Address 500 NORTH BEACON STREET, 4TH FLOOR WATERTOWN MA 02472 857-285-5314
Kymera Therapeutics, Inc. (Filer) CIK: 0001815442 (see all company filings)

EIN.: 812992166 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39460 | Film No.: 251087369
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)